Heart failure drug trial halted early – what went wrong?

NCT ID NCT04318145

Terminated Disease control Sponsor: Palatin Technologies, Inc Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This small study tested a drug called PL-3994 in 15 people with a type of heart failure where the heart pumps normally but doesn't relax properly. The goal was to see if the drug improved heart function and if effects differed between men and women. The trial was terminated early, so we have limited information on its safety or effectiveness.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: PL-3994 (a drug given intravenously to boost heart function)
What this could lead to: If successful, this could point toward a treatment that improves heart function in people with a common type of heart failure.
What could go wrong: This was a very small, early-phase trial that was terminated early, so results are limited. The drug may not work or could have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEART FAILURE WITH PRESERVED EJECTION FRACTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diastolic heart failure heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEART FAILURE WITH PRESERVED EJECTION FRACTION

Contacts and locations

Locations

Northwestern University

Evanston, Illinois, 60208, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.